# Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

> **NCT00908024** · PHASE1,PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 54 (actual)

## Conditions studied

- Colorectal Cancer
- Head and Neck Cancer
- Neoplasm Metastasis

## Interventions

- **DRUG:** BMS-754807
- **DRUG:** cetuximab (Erbitux®)

## Key facts

- **NCT ID:** NCT00908024
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2013-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00908024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00908024, "Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00908024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*